The potential impact of moxidectin on onchocerciasis elimination in Africa: An economic evaluation based on the Phase II clinical trial data

Parasites and Vectors

Volumn 8, Issue 1, 2015, Pages

  Turner, Hugo C ^a   Walker, Martin ^a   Attah, Simon K ^b,c   Opoku, Nicholas O ^b   Awadzi, Kwablah ^b   Kuesel, Annette C ^d   Basáñez, María Gloria ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Onchocerciasis Chemotherapy Research Centre   (Ghana)

^c UNIVERSITY OF GHANA   (Ghana)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Economic evaluation; Ivermectin; Moxidectin; Onchocerciasis; Seasonality

Indexed keywords

IVERMECTIN; MOXIDECTIN; ANTHELMINTIC AGENT; MACROLIDE; MILBEMYCIN;

AFRICA; ARTICLE; COST CONTROL; DRUG COST; DRUG EFFECT; ECONOMIC EVALUATION; HEALTH CARE PERSONNEL; HUMAN; ONCHOCERCIASIS; PARASITE CLEARANCE; PREVALENCE; TIME TO TREATMENT; AFRICA SOUTH OF THE SAHARA; BIOLOGICAL MODEL; ECONOMICS; EPIDEMIOLOGY; HEALTH CARE COST; HEALTH SURVEY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); STATISTICAL MODEL;

AFRICA SOUTH OF THE SAHARA; ANTHELMINTICS; CLINICAL TRIALS, PHASE II AS TOPIC; HEALTH CARE COSTS; HUMANS; IVERMECTIN; MACROLIDES; MODELS, BIOLOGICAL; MODELS, ECONOMIC; ONCHOCERCIASIS; PATIENT COMPLIANCE; POPULATION SURVEILLANCE;

EID: 84926681814     PISSN: None     EISSN: 17563305     Source Type: Journal    
DOI: 10.1186/s13071-015-0779-4     Document Type: Article

References (40)

1. World Health Organization. 18th Session of the Joint Action Forum. Bujumbura, Burundi; 2012. http://www.who.int/apoc/media/Journal-du-FAC-day-4-Anglais.pdf
2. London Declaration on Neglected Tropical Diseases. Ending the neglect and reaching 2020 goals. London, UK; 2012. http://unitingtocombatntds.org/downloads/press/ntd-event-london-declaration-on-ntds.pdf
3. Meredith SEO, Dull HB. Onchocerciasis: The first decade of MectizanTM treatment. Parasitol Today. 1998;14(12):472-4.
4. Eberhard M. Progress toward elimination of onchocerciasis in the Americas - 1993-2012. MMWR Morb Mortal Wkly Rep. 2013;62(20):405-8.
5. World Health Organization. Progress towards eliminating onchocerciasis in the WHO Region of the Americas: verification by WHO of elimination of transmission in Colombia. Wkly Epidemiol Rec. 2013;88(36):381-5.
6. World Health Organization. Onchocerciasis - river blindness. http://www.who.int/mediacentre/factsheets/fs095/en/
7. Diawara L, Traoré MO, Badji A, Bissan Y, Doumbia K, Goita SF, et al. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Negl Trop Dis. 2009;3(7):e497.
8. Traoré MO, Sarr MD, Badji A, Bissan Y, Diawara L, Doumbia K, et al. Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal. PLoS Negl Trop Dis. 2012;6(9):e1825.
9. Ndyomugyenyi R, Lakwo T, Habomugisha P, Male B. Progress towards the elimination of onchocerciasis as a public-health problem in Uganda: opportunities, challenges and the way forward. Ann Trop Med Parasitol. 2007;101(4):323-33.
10. Osei-Atweneboana MY, Eng JKL, Boakye DA, Gyapong JO, Prichard RK. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet. 2007;369(9578):2021-9.
11. World Health Organization, World Health Organization/African Programme for Onchocerciasis Control. Onchocerciasis Control in Special Intervention Zones Including Sierra Leone in the OCP Area. Joint Programme Committee Report. Ouagadougou (Burkina Faso): World Health Organization/African Programme for Onchocerciasis Control; 2002.
12. Turner HC, Walker M, Churcher TS, Osei-Atweneboana MY, Biritwum N-K, Hopkins A, et al. Reaching the London declaration on neglected tropical diseases goals for onchocerciasis: an economic evaluation of increasing the frequency of ivermectin treatment in Africa. Clin Infect Dis. 2014;59(7):923-32.
13. African Programme for Onchocerciasis Control. Conceptual and Operational Framework of Onchocerciasis Elimination with Ivermectin Treatment. WHO/APOC; 2010. http://www.who.int/apoc/oncho-elimination-report-english.pdf
14. Coffeng LE, Stolk WA, Hoerauf A, Habbema D, Bakker R, Hopkins AD, et al. Elimination of African onchocerciasis: modeling the impact of increasing the frequency of ivermectin mass treatment. Plos One. 2014;9(12):e115886.
15. Turner HC, Osei-Atweneboana MY, Walker M, Tettevi EJ, Churcher TS, Asiedu O, et al. The cost of annual versus biannual community-directed treatment with ivermectin: Ghana as a case study. PLoS Negl Trop Dis. 2013;7(9):e2452.
16. Prichard R, Ménez C, Lespine A. Moxidectin and the avermectins: Consanguinity but not identity. Int J Parasitol Drugs Drug Resist. 2012;2:134-53.
17. Awadzi K, Opoku NO, Attah SK, Lazdins-Helds J, Kuesel AC. A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection. PLoS Negl Trop Dis. 2014;8(6):e2953.
18. Filipe JAN, Boussinesq M, Renz A, Collins RC, Vivas-Martinez S, Grillet ME, et al. Human infection patterns and heterogeneous exposure in river blindness. Proc Natl Acad Sci U S A. 2005;102(42):15265-70.
19. Turner HC, Churcher TS, Walker M, Osei-Atweneboana MY, Prichard RK, Basáñez MG. Uncertainty surrounding projections of the long-term impact of ivermectin treatment for human onchocerciasis. PLoS Negl Trop Dis. 2013;7(4):e2169.
20. Basáñez MG, Pion SDS, Boakes E, Filipe JAN, Churcher TS, Boussinesq M. Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8(5):310-22.
21. Turner HC, Walker M, Churcher TS, Basáñez MG. Modelling the impact of ivermectin on River Blindness and its burden of morbidity and mortality in African Savannah: EpiOncho projections. Parasit Vectors. 2014;7:241.
22. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. Oxford: Oxford Science Publications; 1991.
23. World Health Organization. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization. WHO; 2003. http://www.who.int/choice/publications/p-2003-generalised-cea.pdf
24. Taylor MJ, Hoerauf A, Bockarie M. Lymphatic filariasis and onchocerciasis. Lancet. 2010;376(9747):1175-85.
25. Mackenzie CD, Geary TG. Flubendazole: a candidate macrofilaricide for lymphatic filariasis and onchocerciasis field programs. Expert Rev Anti Infect Ther. 2011;9(5):497-501.
26. Mackenzie CD, Geary TG. Addressing the current challenges to finding new anthelminthic drugs. Expert Rev Anti Infect Ther. 2013;11(6):539-41.
27. Walker M, Specht S, Churcher TS, Hoerauf A, Taylor MJ, Basáñez MG: Therapeutic efficacy and macrofilaricidal activity of Doxycycline for the treatment of River Blindness. Clin Infect Dis 2014 Dec 23; pii: ciu1152 [Epub ahead of print].
28. Mackenzie CD, Homeida MM, Hopkins AD, Lawrence JC. Elimination of onchocerciasis from Africa: possible? Trends Parasitol. 2012;28(1):16-22.
29. Hotez PJ, Bottazzi ME, Zhan B, Makepeace BL, Klei TR, Abraham D, et al. The Onchocerciasis Vaccine for Africa - TOVA - Initiative. PLoS Negl Trop Dis. 2015;9(1):e0003422.
30. African Programme for Onchocerciasis Control. Report of the 36th session of the Technical Consultative Committee, Ouagadougou, Burkina Faso; 2013. http://www.who.int/apoc/about/structure/tcc/TCC36-Final-Report-170513.pdf
31. Turner HC, Walker M, French MD, Blake IM, Churcher TS, Basáñez MG. Neglected tools for neglected diseases: mathematical models in economic evaluations. Trends Parasitol. 2014;30(12):562-70.
32. Basáñez MG, Churcher TS, Grillet ME. Onchocerca-Simulium interactions and the population and evolutionary biology of Onchocerca volvulus. Adv Parasitol. 2009;68:263-313.
33. Basáñez MG, French MD, Walker M, Churcher TS. Paradigm lost: how parasite control may alter pattern and process in human helminthiases. Trends Parasitol. 2012;28(4):161-71.
34. Gardon J, Gardon-Wendel N, Demanga N, Kamgno J, Chippaux JP, Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet. 1997;350(9070):18-22.
35. World Health Organization. Criteria for certification of interruption of transmission/elimination of human onchocerciasis. Report of a meeting held in Geneva, 28-29 September 2000. Geneva: WHO; 2001. WHO/CDS/CPE/CEE/2001.18a. http://www.oepa.net/Documentos/CriteriosCertificacionOMS/WHO-CDS-CPE-CEE-2001.18a.pdf
36. Duerr HP, Raddatz G, Eichner M. Control of onchocerciasis in Africa: threshold shifts, breakpoints and rules for elimination. Int J Parasitol. 2011;41(5):581-9.
37. Engelman D, Kiang K, Chosidow O, McCarthy J, Fuller C, Lammie P, et al. Toward the global control of human scabies: introducing the International Alliance for the Control of Scabies. PLoS Negl Trop Dis. 2013;7(8):e2167.
38. African Programme for Onchocerciasis Control. APOC statement on the 2015 annual letter of the Bill & Melinda Gates Foundation. http://www.who.int/apoc/APOC-Statement-on-annual-letter-of-BMGF.pdf?ua=1
39. African Programme for Onchocerciasis Control. Programme for the Elimination of Neglected Diseases in Africa (PENDA). WHO/APOC; 2013. http://www.who.int/apoc/en-apoc
40. Opara KN, Fagbemi OB, Ekwe A, Okenu DM. Status of forest onchocerciasis in the lower cross river basin, Nigeria: entomologic profile after five years of ivermectin intervention. Am J Trop Med Hyg. 2005;73(2):371-6.